If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Mergers & Acquisitions

Chemours sells business, shuffles management

by Alexander H. Tullo
June 9, 2023 | A version of this story appeared in Volume 101, Issue 19


To better focus on core businesses such as fluorinated chemicals and titanium dioxide, Chemours has agreed to sell its glycolic acid business to the private equity firm Iron Path Capital for $137 million. While the company doesn’t break out sales for glycolic acid specifically, the business segment that houses the glycolic acid unit generated revenues of $116 million in 2022. Iron Path has founded the firm PureTech Scientific to run the business. Separately, Chemours has seen three top executives depart in the past 3 months. Chief Financial Officer Sameer Ralhan is leaving the company June 19; he is being replaced by Jonathan Lock, senior vice president and chief development officer, who joined Chemours in 2018. Alisha Bellezza, president of thermal and specialized solutions, resigned in May. And Edwin Sparks, president of titanium technologies and chemical solutions, left the firm at the end of March to lead W. R. Grace. Chemours CEO Mark E. Newman rose to his current position in 2021 after being the firm’s chief financial officer and chief operating officer.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.